CVX

At the latest close of $232.01, CVX trades at 22.33x trailing earnings and 14.76x forward earnings, with a 1.01 PEG, 2.17x price-to-sales, 2.40x price-to-book and 9.70x EV/EBITDA; enterprise value is $491.7 billion versus a $455.1 billion market capitalization. The forward multiple is based on following-year EPS consensus of $15.72, below current-year consensus of $17.51, implying about a 10.3% earnings decline rather than sustainable growth. Reported year-over-year revenue growth of 53.5% and earnings growth of 321.9% are commodity-sensitive and likely affected by comparison effects, so they should not be extrapolated; the PEG near 1.0 is therefore only a rough indicator of value. The 2.17x sales multiple also needs context because commodity prices can inflate revenue without creating durable volume growth. The prior stored analysis cited an approximately 5.9x integrated-peer EV/EBITDA reference, which would make today's 9.70x multiple look premium, but the current bundle has no refreshed peer set or historical CVX valuation range, so that comparison is directional rather than authoritative. The $232.50 mean target implies only about 0.2% upside and the $235 median about 1.3%; the $175 low target implies 24.6% downside while the $272 high target implies 17.2% upside. Overall, valuation is fair-to-full: positive cash generation and the dividend provide support, but the shares do not offer a meaningful margin of safety at this level.

At the October 26 close of $232.01, price is about 7.1% above the SMA20 of $216.65, 10.0% above the EMA50 of $210.82 and 22.8% above the EMA200 of $188.92. EMA50 remains about 11.6% above EMA200, a well-established bullish alignment rather than a cross in close proximity; the SMA20 is also above EMA50. Price is only 0.88% below the $234.08 52-week high, so the long-term trend is strong but extended. On October 26 the stock reached the 52-week high intraday before closing at $232.01, below its $234.08 high and about 0.5% below the prior close.

Q2 2026 EPS was $6.06 versus consensus of $5.57, an 8.84% beat; all six supplied quarters beat estimates, averaging approximately 11.8% surprise, but the series is highly volatile, including a move from $1.41 in Q1 2026 to $6.06 in Q2. The bundle provides neither management guidance nor the post-report share-price reaction, and its current event calendar has no next earnings date; the prior stored analysis identified October 30, so that date should be verified rather than treated as confirmed.

Among the supplied news items, the September 28 Strait of Hormuz and diesel-policy report has the greatest potential to move CVX: the article says Brent rose above $107 after a reported rejection of Iran's proposal, which supports upstream cash flow, while the proposed diesel-export restriction could pressure downstream operations. The two-sided effect is material for an integrated major, but no current crude quote or policy update is included to establish whether the supply premium remains in place.

VIX at 18.39 supports standard rather than crisis sizing, but a 10-year yield near 4.99% exceeds CVX's 3.05% dividend by about 1.94 percentage points and the stock remains exposed to crude prices, global demand and energy policy.

Chevron is a Cyclical Upside holding: its integrated upstream, downstream, chemicals and lubricants businesses, $45.3 billion of operating cash flow and $21.9 billion of free cash flow provide resilience, but earnings remain sensitive to commodity prices, refining margins and energy policy. Net debt is only about 6.3% of market capitalization and the reported beta is 0.52, while the 3.05% dividend is supported by a 67.18% payout ratio. It fits an energy or real-assets Satellite Upside sleeve better than a Core Anchor because consensus implies approximately 10.3% lower EPS in the following year and current valuation leaves little margin of safety. Expect moderate but potentially rapid pullbacks: ATR is about 2.0% of share price, and the supplied history includes a 7.05% decline in five sessions after an earlier overbought reading. The integrated franchise and balance sheet are durable, although the share-price thesis remains cyclical.